Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey

Simple item page
dc.contributor.authorÇelik S.
dc.contributor.authorKlzllay F.
dc.contributor.authorYörükoǧlu K.
dc.contributor.authorAslan G.
dc.contributor.authorOzen H.
dc.contributor.authorAkdogan B.
dc.contributor.authorSozen S.
dc.contributor.authorBaltaci S.
dc.contributor.authorMuezzinoglu T.
dc.contributor.authorIzol V.
dc.contributor.authorBayazlt Y.
dc.contributor.authorNarter F.
dc.contributor.authorTürkeri L.
dc.date.accessioned2024-07-22T08:05:08Z
dc.date.available2024-07-22T08:05:08Z
dc.date.issued2022
dc.description.abstractBackground: Epstein criteria based on sextant biopsy are assumed to be valid for 12-core biopsies. However, very scarce information is present in the current literature to support this view. Objectives: To investigate the validity of Epstein criteria for clinically insignificant prostate cancer (PCa) in a cohort of the currently utilized 12-core prostate biopsy (TRUS-Bx) scheme in patients with low-risk and intermediate-risk PCa. Method: Pathological findings were separately evaluated in the areas matching the sextant biopsy (6-core paramedian) scheme and in all 12-core schemes. Patients were divided into 2 groups according to the final pathology report of RP as true clinically significant PCa (sPCa) and insignificant PCa (insPCa) groups. Predictive factors (including Epstein criteria) and cutoff values for the presence of insPCa were separately evaluated for 6- and 12-core TRUS-Bx schemes. Then, different predictive models based on Epstein criteria with or without additional biopsy findings were created. Results: A total of 442 patients were evaluated. PSA density, biopsy GS, percentage of tumor and number of positive cores, PNI, and HG-PIN were independent predictive factors for insPCa in both TRUS-Bx schemes. For the 12-core scheme, the best cutoff values of tumor percentage and number of positive cores were found to be ≤50% (OR: 3.662) and 1.5 cores (OR: 2.194), respectively. The best predictive model was found to be that which added 3 additional factors (PNI and HG-PIN absence and number of positive cores) to Epstein criteria (OR: 6.041). Conclusions: Using a cutoff value of "1"for the number of positive biopsy cores and absence of biopsy PNI and HG-PIN findings can be more useful for improving the prediction model of the Epstein criteria in the 12-core biopsy scheme. © 2021 Authors.
dc.identifier.DOI-ID10.1159/000513658
dc.identifier.issn00421138
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13006
dc.language.isoEnglish
dc.publisherS. Karger AG
dc.subjectAdult
dc.subjectAged
dc.subjectBiopsy, Large-Core Needle
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProstate
dc.subjectProstatic Neoplasms
dc.subjectRetrospective Studies
dc.subjectTurkey
dc.subjectprostate specific antigen
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectcancer staging
dc.subjectclinical study
dc.subjectcontrolled study
dc.subjectEpstein criteria
dc.subjectGleason score
dc.subjecthuman
dc.subjectintermediate risk patient
dc.subjectlow risk patient
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectperineural invasion
dc.subjectpredictive model
dc.subjectprostate biopsy
dc.subjectprostate cancer
dc.subjectprostatectomy
dc.subjectprostatic intraepithelial neoplasia
dc.subjectretrospective study
dc.subjectsextant biopsy
dc.subjecturogenital tract disease assessment
dc.subjectclinical trial
dc.subjectlarge core needle biopsy
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectpathology
dc.subjectprostate
dc.subjectprostate tumor
dc.subjectturkey (bird)
dc.titleSextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu